Asthika Goonewardene
Stock Analyst at Truist Securities
(1.32)
# 3,559
Out of 4,964 analysts
88
Total ratings
37.93%
Success rate
-12.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRSN Mersana Therapeutics | Maintains: Buy | $250 → $36 | $7.66 | +369.97% | 5 | Aug 14, 2025 | |
| GILD Gilead Sciences | Upgrades: Buy | $108 → $127 | $112.56 | +12.83% | 2 | Aug 8, 2025 | |
| EXEL Exelixis | Maintains: Buy | $56 → $49 | $37.90 | +29.29% | 11 | Jul 29, 2025 | |
| GMAB Genmab | Maintains: Buy | $45 → $46 | $25.11 | +83.19% | 15 | Jul 8, 2025 | |
| BNTX BioNTech SE | Reiterates: Buy | $151 → $155 | $101.93 | +52.07% | 3 | Jun 3, 2025 | |
| LEGN Legend Biotech | Maintains: Buy | $88 → $71 | $34.37 | +106.58% | 2 | May 14, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 → $10 | $1.18 | +747.46% | 7 | May 14, 2025 | |
| AUTL Autolus Therapeutics | Maintains: Buy | $11 → $10 | $1.57 | +536.94% | 4 | Apr 1, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $25 → $15 | $2.23 | +572.65% | 6 | Mar 3, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $35 | $24.42 | +43.33% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $87 → $136 | $70.25 | +93.59% | 5 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $0.90 | +1,575.23% | 6 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $44 | $10.61 | +314.70% | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $69 → $88 | $66.10 | +33.13% | 2 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.40 | +185.71% | 5 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 | $1.94 | +879.38% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $27 | $0.76 | +3,459.19% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Hold | $120 | $27.63 | +334.39% | 1 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $100 → $60 | $3.85 | +1,458.44% | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $228 → $180 | $5.13 | +3,408.77% | 4 | Aug 23, 2022 |
Mersana Therapeutics
Aug 14, 2025
Maintains: Buy
Price Target: $250 → $36
Current: $7.66
Upside: +369.97%
Gilead Sciences
Aug 8, 2025
Upgrades: Buy
Price Target: $108 → $127
Current: $112.56
Upside: +12.83%
Exelixis
Jul 29, 2025
Maintains: Buy
Price Target: $56 → $49
Current: $37.90
Upside: +29.29%
Genmab
Jul 8, 2025
Maintains: Buy
Price Target: $45 → $46
Current: $25.11
Upside: +83.19%
BioNTech SE
Jun 3, 2025
Reiterates: Buy
Price Target: $151 → $155
Current: $101.93
Upside: +52.07%
Legend Biotech
May 14, 2025
Maintains: Buy
Price Target: $88 → $71
Current: $34.37
Upside: +106.58%
Allogene Therapeutics
May 14, 2025
Maintains: Buy
Price Target: $14 → $10
Current: $1.18
Upside: +747.46%
Autolus Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $1.57
Upside: +536.94%
Iovance Biotherapeutics
Mar 3, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $2.23
Upside: +572.65%
Summit Therapeutics
Jan 8, 2025
Initiates: Buy
Price Target: $35
Current: $24.42
Upside: +43.33%
Nov 12, 2024
Maintains: Buy
Price Target: $87 → $136
Current: $70.25
Upside: +93.59%
Aug 16, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $0.90
Upside: +1,575.23%
Jun 24, 2024
Maintains: Buy
Price Target: $50 → $44
Current: $10.61
Upside: +314.70%
Jun 4, 2024
Maintains: Buy
Price Target: $69 → $88
Current: $66.10
Upside: +33.13%
May 21, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $1.40
Upside: +185.71%
May 16, 2024
Maintains: Buy
Price Target: $19
Current: $1.94
Upside: +879.38%
Sep 6, 2023
Reiterates: Buy
Price Target: $27
Current: $0.76
Upside: +3,459.19%
Apr 5, 2023
Reinstates: Hold
Price Target: $120
Current: $27.63
Upside: +334.39%
Aug 23, 2022
Maintains: Hold
Price Target: $100 → $60
Current: $3.85
Upside: +1,458.44%
Aug 23, 2022
Maintains: Buy
Price Target: $228 → $180
Current: $5.13
Upside: +3,408.77%